1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma

Journal of Medicinal Chemistry

Volumn 41, Issue 6, 1998, Pages 821-835

  Christensen, Siegfried B ^a   Guider, Aimee ^a   Forster, Cornelia J ^a   Gleason, John G ^a   Bender, Paul E ^a   Karpinski, Joseph M ^a   Dewolf Jr , Walter E ^a   Barnette, Mary S ^a   Underwood, David C ^a   Griswold, Don E ^a   Cieslinski, Lenora B ^a   Burman, Miriam ^a   Bochnowicz, Steven ^a   Osborn, Ruth R ^a   Manning, Carol D ^a   Grous, Marilyn ^a   Hillegas, Leonard M ^a   Bartus, Joan O'Leary ^a   Dominic Ryan, M ^a   Eggleston, Drake S ^a   Curtis Haltiwanger, R ^a   Torphy, Theodore J ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 CYANO 4 [3 CYCLOPENTYLOXY 4 METHOXY PHENYL] 1 CYCLOHEXANECARBOXYLIC ACID; ANTIGEN; CILOMILAST; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; RESERPINE; ROLIPRAM; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTHMA; BINDING SITE; BRONCHOSPASM; CENTRAL NERVOUS SYSTEM; DOG; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; ENZYME INHIBITION; GUINEA PIG; HUMAN; HUMAN CELL; HYPOTHERMIA; INTRAVENOUS DRUG ADMINISTRATION; MAST CELL DEGRANULATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; RABBIT; STRUCTURE ACTIVITY RELATION; VOMITING; X RAY CRYSTALLOGRAPHY;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BINDING, COMPETITIVE; BODY TEMPERATURE; BRAIN; BRONCHOCONSTRICTION; CYCLOHEXANECARBOXYLIC ACIDS; DOGS; GASTRIC ACID; GUINEA PIGS; HUMANS; MICE; MONOCYTES; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; RABBITS; RECOMBINANT PROTEINS; ROLIPRAM; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA; VOMITING;

EID: 14444268769     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970090r     Document Type: Article

References (95)

1. Bourne, H. R.; Lichtenstein, L. M.; Melmon, K. L.; Henny, C. S.; Weinstein, Y.; Shearer, G. M. Modulation of inflammation and immunity by cyclic AMP. Receptors for vasoactive hormones and mediators of inflammation regulate many leukocyte functions. Science 1974, 184, 19-28.
2. Flaut, M.; Marone, G.; Thomas, L. L.; Lichtenstein, L. M. Cyclic nucleotides in immune responses and allergy. Adv. Cyclic Nudeotide Res. 1980, 12, 161-172.
3. Kuehl, F. A.; Zanetti, M. E.; Soderman, D. D.; Miller, D. K.; Harn, E. A. Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma. Am. Rev. Resp. Dis. 1987, 136, 210-213.
4. Beavo, J. A. Multiple isozymes of cyclic nucleotide phosphodiesterase. In Advances in Second Messenger and Phosphorylation Research; Greengard, P., Robinson, G. A., Eds.; Raven Press: New York, 1988; Vol. 22, pp 1-38.
5. Beavo, J. A. and Reifsnyder, D. H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sei. 1990, 11, 150-155.
6. Torphy, T. J.; Hay, D. W. P. Biochemical regulation of airway smooth muscle tone: An overview. In Airway Smooth Muscle: Modulation of Receptors and Response; CRC Press: Boca Raton, 1990; pp 39-68.
7. Kammer, G. M. The adenylate cyclase-cAMP-protein kinase pathway and regulation of immune response. Immunol. Today 1988, 9, 222-229.
8. Torphy, T. J.; Undem, B. J. Phosphodiesterase inhibitors: New opportunities for the treatment of asthma. Thorax 1991, 46, 512-523.
9. Nicholson, C. D.; Challiss, R. A. J.; Shahid, M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isozymes. Trends Pharmacol. Sei. 1991,12, 19-27.
10. Giembycz, M. A.; Dent, G. Prospects for selective cyclic nucleotide phosphodiesterase inhibitors in the treatment of asthma. Clin. Exp. Allergy 1993, 22, 337-344.
11. Beavo, J. A., Conti, M.; Heaslip, R. J. Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 1994, 46, 399-405.
12. Beavo, J. A. Cyclic nucleotide phosphodiesterases: Functional implications of multiple forms. Physiol. Rev. 1995, 75, 725-748.
13. Weishaar, R. E.; Cain, M. H.; Bristol, J. A. A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J. Med. Chem. 1985, 28, 537-545.
14. Torphy, T. J.; Livi, G. P.; Christensen, S. B. Novel phosphodiesterase inhibitors for the therapy of asthma. Drug News Perspect. 1993, 6, 203-214.
15. Christensen, S. B.; Torphy, T. J. Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. In Annual Reports in Medicinal Chemistry; Bristol, J. A., Ed.; Academic Press: New York, 1994; Vol. 29, pp 185-194.
16. Palfreyman, M. N. Phosphodiesterase type IV inhibitors as antiinflammatory agents. Drugs Future 1995, 20, 793-804.
17. Cavalla, D.; Firth, R. Phosphodiesterase IV inhibitors: Structural diversity and therapeutic potential in asthma. Curr. Med. Chem. 1995, 2, 561-572.
18. Torphy, T. J.; Livi, G. P.; Balcarek, J. M.; White J. R.; Undem, B. J. Therapeutic potential for isozyme-selective phosphodiesterase inhibitors in the treatment of asthma. In Advances in Second Messenger and Phosphorylation Research', Greengard, P., Robinson, G. A., Eds.; Raven Press: New York, 1988; Vol. 25, pp 289-305.
19. Peachell, P. T.; Undem, B. J.; Schleimer, R. P.; MacGlashan, D. W.; Lichtenstein, L. M.; Cieslinski, L. B.; Torphy, T. J. Preliminary identification and role of phosphodiesterase isozymes in human basophils. J. Immunol. 1992, 148, 2503-2510.
20. Kleine-Tebbe, J.; Wicht, L.; Gagne, H.; Friese, A.; Schunack, W.; Schudt, C.; Kunkel, G. Inhibition of IgE-mediated histamine release from human peripheral leukocytes by selective phosphodiesterase inhibitors. Agents Actions 1992, 36, 200-206.
21. Dent, G.; Giembycz, M. A.; Evans, P. M.; Rabe, K. F.; Barnes, P. J. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibiton of type IV phosphodiesterase: Interaction with the beta adrenoceptor agonist albuterol. J. Pharmacol. Exp. Ther. 1994, 277, 1167-1174.
22. Hatzelmann, A.; Tenor, H.; Schudt, C. Differential effects of nonselective and selective phosphodiesterase inhibitors on human eosinophils. Br. J. Pharmacol. 1995, 114, 821-831.
23. Nielson, P.; Vestal, R. E.; Sturm, R. J.; Heaslip, R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J. Allergy Clin. Immunol. 1990,86, 801-808.
24. Schudt, C.; Winder, S.; Forderkunz, S.; Hatzelmann, A.; Ullrich, V. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Cas. NaunynSchmiedeberg's Arch. Pharmacol. 1991, 344, 682-690.
25. Semmler, J.; Wachtel, H.; Endres, S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-a production by human mononuclear cells. Int. J. Immunopharmacol. 1993, 15, 409-413.
26. Schade, F. U.; Schudt, C. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumor necrosis factor by macrophages. Eur. J. Pharmacol. 1993, 230, 9-14.
27. Molnar-Kimber, K. L.; Yonno, L.; Heaslip, R. J.; Weichman, B. M. Differential regulation of TNF-α and IL-1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors. Med. Inflamm. 1992, 1, 411-417.
28. Prabhakar, U.; Lipshutz, D.; O'Leary Bartus, J.; Slivjak, M. J.; Smith, E. F.; Esser, K. Characterization of cAMP-dependent inhibition of LPS-induced TNFa production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 1994, 16, 805-816.
29. Verghese, M. W.; McConnell, R. T.; Strickland, A. B.; Gooding, R. C.; Stimpson, S. A.; Yarnall, D. P.; Taylor, J. D.; Furdon, P. J. Differential regulation of human monocyte-derived TNFa and IL-1/3 by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. J. Pharmacol. Exp. Ther. 1995, 272, 1313-1320.
30. Essayan, D. M.; Huang, S.-K.; Undem, B. J.; Kagey-Sobotka, A.; Lichtenstein, L. M. Modulation of antigen- and mitogen-induced proliferative responses of peripheral blood mononuclear cells by nonselective and isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J. Immunol. 1994, 753, 3408-3416.
31. Fischer, W.; Schudt, C.; Wendel, A. Protection by phosphodiesterase inhibitors against endotoxin-induced liver injury in galactosamine-sensitized mice. Biochem. Pharmacol. 1993, 45, 2399-2404.
32. Badger, A. M.; Olivera, D. L.; Esser, K. Beneficial effect of the phosphodiesterase inhibitors, BRL 61063, pentoxifylline, and rolipram in a murine model of endotoxin shock. Circ. Shock 1994, 44, 188-195.
33. Howell, R. E.; Sickels, B. D.; Woeppel, S. L. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs. J. Pharmacol. Exp. Ther. 1993, 264, 609-615.
34. Underwood, D. C.; Osborn, R. R.; Novak, L. B.; Matthews, J. K; Newsholme, S. J.; Undem, B. J.; Hand, J. B.; Torphy, T. J. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J. Pharmacol. Exp. Ther. 1993, 266, 306-313.
35. Sturm, R. J.; Osborne, M. C.; Heaslip, R. J. The effect of phosphodiesterase inhibitors on pulmonary inflammatory cell influx in ovalbumin sensitized guinea pigs. J. Cell. Biochem. 1990, 14C, 337.
36. Cortijo, J.; Bou, J.; Beleta, J.; Cardelüs, I.; Llenas, J.; Morcillo, E.; Gristwood, R. W. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br. J. Pharmacol. 1993, 108, 562-568.
37. DeBoer, J., A.; Philpott, A. J.; VanAmsterdam, R. G. M.; Shahid, M.; Zaagsma, J.; Nicholson, D. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 1992, 706, 1028-1034.
38. Torphy, T. J.; Undem, B. J.; Cieslinski, L. B.; Luttmann, M. A.; Reeves, M. K.; Hay, D. W. P. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J. Pharmacol. Exp. Ther. 1993,265,1213-1223.
39. Carpenter, D. O.; Briggs, D. B.; Knox, A. P.; Strominger, N. Excitation of area postrema neurons by transmitters, peptides, and cyclic nucleotides. J. Neurophys. 1988, 59, 358-369.
40. Eben, E.; Rüther, E. Animal trial prediction and clinical effect of new chemical substances to be used as antipsychotic agents. Pharmacopsychiatry 1985,18, 69-70.
41. Horowski, R.; Sastre-y-Hernandez, M. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr. Ther. Res. 1985, 38, 23-29.
42. Puurunen, J.; Lücke, C.; Schwabe, U. Effect of the phosphodiesterase inhibitor 4-[3-(cyclopentyloxy)-4-methoxyphenyI]-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP. Naunyn-Schmiedeberg's Arch. Pharmacol. 1978, 304, 69-75.
43. Eckmann, F.; Fichte, K.; Meya, U.; Sastre-y-Hernandez, M. Rolipram in major depression: results of a double-blind comparative study with amitriptyline. Curr. Ther. Res. 1988, 43, 291-295.
44. Wachtel, H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodi-esterase inhibitors. Neuropharmacology 1983, 22, 267-272.
45. Zeller, E.; Stief, H.-J.; Pflug, B.; Sastre-y-Hernandez, M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984, 17, 188-190.
46. Bobon, D.; Breulet, M.; Gerard-Vandenhove, M.-A.; GuiotGoffioul, F.; Plomteux, G.; Sastre-y-Hernandez, M.; Schratzer, M.; Troisfontaines, B.; von Frenckell, R; Wachtel, H. Is phosphodiesterase inhibition a new mechanism of antidepressant action? Eur. Arch. Psychiatr. Neural. Sei. 1988, 238, 2-6.
47. Torphy, T. J.; Stadel, J. M.; Burman, M.; Cieslinski, L. B.; AIcLaughlin, M. M.; White, J.; Livi, G. P. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J. Biol. Chem. 1992, 267, 1798-1804.
48. Schneider, H. H.; Schmiechen, R.; Brezinski, M.; Seidler, J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 1986, 727, 105-115.
49. Jacobitz, S.; McLaughlin, M. M.; Livi, G. P.; Torphy, T. J. Mapping the functional domains of human recombinant phosphodiesterase 4A. Structural requirements for catalytic activity and rolipram binding. Mol. Pharmacol. 1996, 50, 891-899.
50. Christensen, S. B.; DeWolf, Jr., W. E.; Ryan, M. D.; Torphy, T. J. Molecular aspects of inhibitor interaction with PDE4. In Phosphodiesterase Inhibitors', Academic Press: San Diego, 1996; pp 185-207.
51. Barnette, M. S.; O'Leary Bartus, J.; Burman, M.; Christensen, S. B.; Cieslinski, L. B.; Esser, K. M.; Prabhakar, U. S.; Rush, J. A.; Torphy, T. J. Association of the antiinflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding. Biochem. Pharmacol. 1996, 57, 949-956.
52. Barnette, M. S.; Grous, M.; Cieslinski, L. B.; Burman, M.; Christensen, S. B.; Torphy, T. J. Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J. Pharmacol. Exp. Ther. 1995, 273, 1369-1402.
53. Baures, P. W.; Eggleston, D. S.; Erhard, K. F.; Cieslinski, L. B.; Torphy T. J.; Christensen, S. B. The crystal structure, absolute configuration and phosphodiesterase inhibitory activity of (+)-l-(4-bromobenzyl)-4-[3-(cyclopentyloxy)-4-methoxyphenyl]pyrrolidin-2-one. J. Med. Chem. 1993, 36, 3274-3277.
54. Ram, S.; Ehrenkaufer, R. E. A general procedure for mild and rapid reduction of aliphatic and aromatic nitro compounds using ammonium formate as a catalytic hydrogen transfer agent. Tetrahedron Lett. 1984, 25, 3415-3418.
55. Schmiechen, R.; Horowski, R.; Palenschat, D.; Paschelke, G.; Wachtel, H.; Kehr, W. 4-(Polyalkoxyphenyl)-2-pyrrolidinones. U.S. Patent 4,012, 495, March 15, 1977.
56. Aizpurua, J. AI.; Palomo, C. Synthesis of benzyl halides from aldehydes by halosilanes and 1,1,3,3-tetramethyldisiloxane. Tetrahedron Lett. 1984, 25, 1103-1104.
57. Weinstock, J.; Ladd, D. L.; Wilson, J. W.; Brush, C. K.; Yim, N. C. F.; Gallagher, Jr., G.; McCarthy, AI. E.; Silvestri, J.; Sarau, H. AI.; Fliam, K. E.; Ackerman, D. M.; Setler, P. E.; Tobia, A. J.; Hahn, R. A. Synthesis and renal vasodilator activity of some dopamine agonist l-aryl-2,3,4,5-tetrahydro-lH-3-benzazepine-7,8-diols: Halogen and methyl analogs of fenoldopam. J. Med. Chem. 1986, 29, 2315-2325.
58. Lednicer, D.; VonVoigtlander, P. F.; Emmert, E. 4-Amino-4-arylcyclohexanones and their derivatives, a novel class of analgesics. 1. Alodification of the aryl ring. J. Med. Chem. 1980, 23, 424-430.
59. Banerjee, D. K.; Mahapatra, S. N. Synthesis of 1,3-dimethyll,3-dicyclohexane-2-acetic acid. Tetrahedron 1960,11,234-240.
60. Krapcho, A. P.; Lovey, A. J. Decarboxylation of geminal diesters, -keto esters and a-cyano esters effected by sodium chloride in dimethyl sulfoxide. Tetrahedron Lett. 1973, 12, 957-960.
61. Jones, P. F.; Läppert, M. F. Wittig-type reaction of 2-lithio2-trimethylsilyl-l,3-dithian: An improved and extended synthesis of alkylidenedithianes for 1-carbon homologation. J. Chem. Soc., Chem. Commun. 1972, 526.
62. Duncia, J. V.; Pierce, M. E.; Santella, J. B., III. Three synthetic routes to a sterically hindered tetrazole. A new one-step mild conversion of an amide into a tetrazole. J. Org. Chem. 1991,56, 2395-2400.
63. Marshall, J. A.; Bierenbaum, R. Synthesis of olefins via reduction-decyanation of β,γ-nitriles. J. Org. Chem. 1977, 42, 3309-3311.
64. Corey, E. J.; Suggs, J. W. Pyridinium chlorochromate. An effective reagent for oxidation of primary and secondary alcohols to carbonyl compounds. Tetrahedron Lett. 1975,14,2647-2650.
65. Wulff, W. D.; Xu, Y.-C. An organochromium-mediated synthesis of 11-deoxidaunomycinone via tandem benzannulation/FriedelCraRs double cyclization. J. Am. Chem. Soc. 1988,110, 2312-2315.
66. Wenkert, E.; Goodwin, T. E. 4-Formyl-2-cyclohexenone derivative.s. Synth.Commun. 1977, 7, 409-415.
67. Noller, C. R. O-Toluamide. Organic . Syntheses; Wiley: New York, 1943; Collect. Vol. H, p 586.
68. Stevens, R. V.; DuPree, L. E.; Loewenstein, P. L. General methods of alkaloid synthesis. A new approach to the synthesis of the 5,10b-ethanophenanthridine Amaryllidaceae alkaloids. A stereosclective total synthesis of dl-elwesine (dihydrocrinine). J. Org. Chem. 1972, 37, 977-981.
69. Gilbert, J. C.; Weerasooriya, U. Elaboration of aldehydes and ketones to alkynes: Improved methodology. J. Org. Chem. 1979, 44, 4997-4998.
70. Chaikin, S. W.; Brown, W. G. Reduction of aldehydes, ketones and acid chlorides by sodium borohydride. J. Am. Chem. Soc. 1949, 71, 122-125.
71. Middleton, W. J. New fluorinating reagents. Dialkylaminosulfur fluorides. J. Org. Chem. 1975, 40, 574-578.
72. Maschler, H.; Christensen, S. B. Phenyl-substituted cycloalkenyl compounds useful as PDE IV inhibitors. U.S. Patent 5,362,915, 1994.
73. Christensen, S. B.; Levy, M. Cyclopentane and cyclopentene derivatives with antiallergic, and anti-inflammatory and antitumor necrosis factor activity. WO9307111, 1993.
74. Jackman, L.; Sternhell, S. Applications of Nuclear Magnetic Resonance Spectroscopy in Organic Chemistry; Pergamon Press: Oxford, 1969; pp 289-291.
75. Marivet, M. C.; Bourguignon, J.-J.; Lugnier, C.; Mann, A.; Stoclet, J.-C.; Wermuth, C.-G. Inhibition of cyclic adenosine-3',5'phosphate phosphodiesterase from vascular smooth muscle by rolipram analogues. J. Med. Chem. 1989, 32, 1450-1457.
76. Schmiechen, R.; Schneider, H. H.; Watchel, H. Close correlation between behavioral response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology 1990, 702, 17-20.
77. Schultz, J. E.; Schmidt, B. H. Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causes β-adrenoceptor subsensitivity in rat cerebral cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 1986, 333, 23-30.
78. Barnette, M. S. Challenges for drug discovery. New Drugs for Asthma-Ill, Montebello, Québec, July 1994.
79. Griswold, D. E.; Hillegas, L. M.; O'Leary-Bartus, J.; Lee, J. C.; Laydon, J. T.; Torphy, T. J. Utilization of adoptively transferred human monocytes in Balb/c mice to evaluate inflammatory cytokine production. J. Immunol. Methods 1996, 795, 1-5.
80. Wachtel, H. Species differences in behavioral effects of rolipram and other adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitors. J. Neural Transmission 1983, 56, 139152.
81. Koe, B. K.; Lebel, L. A.; Nielsen, J. A.; Russo, L. L.; Saccomano, N. A.; Vinick, F. J.; Williams, I. H. Effects of novel catechol ether imidazolidinones on calcium-independent phosphodiesterase activity, [3H]rolipram binding, and reserpine-induced hypothermia in mice. Drug Dev. Res. 1990, 21, 135-142.
82. Pinto, I. L.; Buckle, D. R.; Readshaw, S. A.; Smith, D. G. The selective inhibition of phosphodiesterase IV by benzopyran derivatives of rolipram. Bioorg. Med. Chem. Lett. 1993,3,1743-1746.
83. Buckle, D. R.; Arch, J. R. S.; Conolly, B. J.; Fenwick, A. E.; Forster, K. A.; Murray, K. J.; Readshaw, S. A.; Smallridge, M.; Smith, D. G. Inhibition of cyclic nucleotide phosphodiesterase by derivatives of l,3-bis(cyclopropylmethyl)xanthine. J. Med. Chem. 1994, 37, 476-485.
84. 3H]rolipram binding site: 3-Norbornyloxy-4-methoxyphenylmethylene oxindoles. Bioorg. Med. Chem. Lett. 1995, 5, 1965-1968.
85. 3H]rolipram binding site. Bioorg. Med. Chem. Lett. 1995, 5, 1969-1972.
86. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 1996, 39, 120-125.
87. 3H]rolipram. Brain Res. 1989, 503, 229-245.
88. Souness, J. E.; Scott, L. C. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem. J. 1993, 291, 389-395.
89. m cyclic AMP phosphodiesterase inhibition in trachéal relaxation and bronchodilation in the guinea pig. J. Pharmacol. Exp. Ther. 1989,257, 199-207.
90. Barnette, M. S.; Manning, C. D.; Cieslinski, L. B.; Burman, M.; Christensen, S. B.; Torphy, T. J. The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity. J. Pharmacol. Exp. Ther. 1995,273, 674-679.
91. Sheldrick, G. M. SHELXS-86, University of Gottingen, Germany, 1986.
92. Sheldrick, G. M. SHELXL-93, University of Gottingen, Germany, 1993.
93. International Table for X-ray Crystallography, Vol. TV; Kynoch Press: Birmingham, 1974 (Present Distributor D. Reidel, Dordrecht.).
94. Torphy, T. J.; Cieslinski, L. B. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine trachéal smooth muscle. Mol. Pharmacol. 1990,37,206-214.
95. Reeves, M. L.; Leigh, B. K.; England, P. J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem. J. 1987, 241, 535-541.